IBUPROFEN TABLET
Riik: Kanada
keel: inglise
Allikas: Health Canada
Toote omadused
(SPC)
26-02-2020
Mõned selle toote dokumendid pole praegu saadaval. Võite saata päringu meie klienditeenindusele ja me teavitame teid sellest niipea, kui meil on neid võimalik hankida.
Saada päring.
Saada päring.
Toimeaine:
IBUPROFEN
Saadav alates:
ANGITA PHARMA INC.
ATC kood:
M01AE01
INN (Rahvusvaheline Nimetus):
IBUPROFEN
Annus:
200MG
Ravimvorm:
TABLET
Koostis:
IBUPROFEN 200MG
Manustamisviis:
ORAL
Ühikuid pakis:
100
Retsepti tüüp:
OTC
Terapeutiline ala:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Toote kokkuvõte:
Active ingredient group (AIG) number: 0108883004; AHFS:
Volitamisolek:
APPROVED
Loa andmise kuupäev:
2020-04-23
Toote omadused
_Page 1 / 40_
PRODUCT MONOGRAPH
IBUPROFEN
Ibuprofen Tablets USP
200mg and 400 mg
Non-Steroidal Anti-inflammatory Drug
Analgesic, Antipyretic Agent
Angita Pharma Inc.
1310 Nobel Street,
Boucherville,
Québec Canada, J4B 5H3
Date of Preparation: February 26, 2020
Control # 236574
_Page 2 / 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINCAL USE
...........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
9
DRUG INTERACTIONS
..............................................................................................................
12
DOSAGE AND ADMINISTRATION
..........................................................................................
15
OVERDOSAGE
..................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
16
STORAGE AND STABILITY
......................................................................................................
17
SPECIAL HANDLING INSTRUCTIONS
..................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 18
PART II: SCIENTIFIC INFORMATION
................................................................................
19
PHARMACEUTICAL INFORMATION
..................
Lugege kogu dokumenti
